Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Computer Software

Completed

Conditions studied: Bacterial Infections

In brief

We will compare the percentage of patients having therapeutic vancomycin serum concentrations after current standard dosing, after dosing with our software. We will also include therapeutic outcomes and costs in the analysis.

Key facts

Study ID

NCT01932034

Run by

Children's Hospital Los Angeles

People needed

263

Starts

2012-09-01

Expected to finish

2016-07-04

Last updated by the study team

2018-02-20

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hospitalized infants, children, adolescents, and adults who require, but have not started vancomycin therapy for infections with suspected or proven beta-lactam resistant gram-positive bacteria will eligible for enrollment.
• Participants will of any age.
• Participant/parent/legal guardian (as applicable) must be able and willing to provide signed informed consent.

You may not qualify if…

• Prior receipt of vancomycin for the same clinical event (e.g. the same fever of unknown origin in a neutropenic patient defined as <24 hours of no fever)
• Known colonization or infection with a vancomycin resistant organism (MIC > 2 mg/L)
• Known hypersensitivity or intolerance to vancomycin
• Patients on any form of dialysis
• Not expected to survive >72 hours.

Where it is running

• Los Angeles County - University of Southern California Medical Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.